<DOC>
	<DOCNO>NCT01146288</DOCNO>
	<brief_summary>Background : Obesity associate high prevalence chronic kidney disease.The glomerular hyperfiltration associate obesity may play role pathogenesis obesity associate chronic kidney disease . Attenuation hyperfiltration pharmacological mean may slow development progression chronic renal failure . The investigator previously show acetazolamide , proximally act diuretic activates tubuloglomerular feedback ( TGF ) increase solute delivery Macula DENSA , abate glomerular hyperfiltration . The present study design test hypothesis decrease hyperfiltration specific acetazolamide due non specific diuretic effect . The aim present study compare effect furosemide acetazolamide glomerular hemodynamics subject severe obesity . Methods : A randomized double-blind crossover control design use . Fifteen obese subject ten subject normal body weight participate study . Obese subject undergo measurement glomerular filtration rate ( GFR ) ( inulin clearance ) , renal plasma flow ( RPF ) ( p-aminohippuric acid clearance ) , filtration fraction , fractional excretion lithium ( FE LI ) blood pressure , intravenous administration furosemide 2 mg. acetazolamide 5 mg/kg BW . Ten subject normal body weight undergo measurement renal function without administration diuretic .</brief_summary>
	<brief_title>Effect Acetazolamide Furosemide Obesity-induced Glomerular Hyperfiltration</brief_title>
	<detailed_description>BACKGROUND Almost half cause death industrial world due cardio-vascular ( CV ) disease . Two main risk factor CV disease become much prevalent last decade , reach epidemic dimension 21st century : hypertension obesity . In 2003-2004 , 66 % adult USA population body mass index ( BMI ) 25 , 32 % BMI 30 .Hypertension prevalent obese lean subject .The cause effect relationship two condition support fact weight loss associate decrease blood pressure . Salt retention kidney one important mechanism involve pathogenesis hypertension obesity . Studies animal model human show increased salt reabsorption occur tubule obesity . Another renal functional abnormality occur obesity glomerular hyperfiltration , characterize increase renal plasma flow ( RPF ) increase glomerular filtration rate ( GFR ) twice normal level . The structural basis functional abnormality renal hypertrophy glomerular enlargement . These functional structural abnormality deleterious consequence : 1 . Increased urinary albumin excretion . Microalbuminuria , important risk factor CV disease , high prevalence obese subject . 2 . Increased risk development focal segmental glomerulosclerosis , so-called obesity relate glomerulopathy . The incidence disease multiply 10 time within 15 yrs USA . 3 . Increased rate progression chronic renal insufficiency kidney disease primarily cause obesity . Following initial glomerular damage cause , number remnant function glomerulus decrease . The consequent compensatory increase single nephron filtration rate remnant glomerulus lead glomerular damage kidney disease related obesity . In obese chronic renal damage , obesity relate hyperfiltration amplifies compensatory augmentation single nephron GFR remnant nephron , thus worsen glomerular damage , irrespective cause primary insult . The clinical relevance abnormality reflect sharp increase risk develop end stage renal disease obese . This relative risk , independently confounders diabetes mellitus , hypertension dyslipidemia , 3 5 depend severity obesity . Considering role hyperfiltration pathogenesis chronic kidney disease ( CKD ) obese , attenuation hyperfiltration pharmacological mean may slow development progression chronic renal failure . One tool available activate tubuloglomerular feedback ( TGF ) . Tubuloglomerular feedback ( TGF ) refers alteration GFR induce change tubular flow rate . An increase delivery chloride Macula DENSA result reduction GFR , result decrease tubular flow rate deliver Macula DENSA . An increase chloride delivery Macula DENSA obtain administrate acetazolamide , diuretic act proximal tubule . We previously show administration acetazolamide obese subject result attenuation glomerular hyperfiltration . The aim present study show effect acetazolamide GFR specific due diuretic effect . We study effect furosemide , diuretic activate TGF , GFR RPF obese subject comparison acetazolamide . Methods : A 24-hour urine collection perform week prior renal function test study assessment sodium intake . Obese subject : A randomized double-blind crossover control design use . Two renal function study perform : one intravenous furosemide second intravenous acetazolamide . Subjects receive 300 mg lithium carbonate 22.00 day renal function test . They instruct drink 250 ml water bedtime . Renal function test start 08.00 a.m. 10-hour fast , except drink 250 ml water 07.00 a.m. Intravenous catheter place upper limb infusion clearance marker blood sample . After blood sample urea , creatinine , protein , glucose , electrolytes , blood gas , insulin , renin , aldosterone , Hba1c , CBC . A prim dose inulin ( 50 mg/kg ) p-aminohippuric acid ( 8 mg/kg ) administer 200-300 ml p.o water load give . Thereafter , inulin p-aminohippuric acid infuse continuously . After first 60 minute , 8 accurately timed urine collection 30 40 minute obtain spontaneous voiding . Peripheral venous blood drawn bracket urine collection . Arterial pressure measure trained observer , 30 minute rest supine position , use electronic oscillometric blood pressure measure device . The cuff appropriately size diameter arm arm position heart level . At least 8 measurement perform study , measurement mean 3 reading . After first 4 timed urine collection , participant receive intravenous furosemide 2 mg/5min intravenous acetazolamide 5 mg/kg/5 min . Four time urine collection perform thereafter . Subjects randomize receive first study either furosemide acetazolamide . The second study perform one two week first study , use drug administrate first study . Subjects normal body weight : undergo measurement renal function without administration diuretic ( one renal function study , protocol like obese subject , 4 urine collection ) . Laboratory procedure : Plasma urinary concentration inulin p-aminohippuric acid analyze colorimetric method .Lithium serum urine measure . Urine microalbumin determine competitive chemiluminescent enzyme immunoassay . Calculations : GFR determine average value time inulin clearance , renal plasma flow ( RPF ) - average value time p-aminohippurate clearance . The fractional excretion lithium ( FE Li ) calculate lithium clearance / GFR , use two timed urine collection . FE Li determine average value two measurement Statistical Analysis : The significance difference group evaluate paired unpaired two-tailed Student 's t-test . The Student 's t-test applied non-normally distribute data ( albumin excretion rate fractional lithium excretion ) log transformation . P &lt; 0.05 consider significant . The response treatment furosemide compare response treatment acetazolamide use ANOVA .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Acetazolamide</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>15 obese men ( BMI &gt; 30 ) , age 18 55 , glomerular hyperfiltration ( creatinine clearance &gt; 130 ml/min ) ) 10 normal body weight men ( BMI &lt; 25 ) , age 18 55 . Heart failure , CKD , COPD Known allergy furosemide , acetazolamide , inulin aminohippurate Pharmacologic treatment hypertension , cardiac disease , diabetes mellitus Treatment corticosteroid , antiepileptic NSAID</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>obesity</keyword>
	<keyword>acetazolamide</keyword>
	<keyword>furosemide</keyword>
</DOC>